Beam Therapeutics Inc.
BEAM
$25.17
-$0.15-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 279.52% | -32.03% | -28.08% | 0.81% | -90.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 279.52% | -32.03% | -28.08% | 0.81% | -90.49% |
| Cost of Revenue | -2.14% | 16.46% | 16.91% | 16.50% | -27.58% |
| Gross Profit | 120.78% | -25.11% | -23.94% | -18.01% | -140.53% |
| SG&A Expenses | 12.63% | 0.85% | -9.34% | 4.55% | -33.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11% | 13.03% | 10.24% | 13.64% | -29.03% |
| Operating Income | 82.56% | -19.07% | -14.54% | -14.55% | -175.30% |
| Income Before Tax | 370.38% | -16.61% | -12.39% | -10.74% | -162.67% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | 370.38% | -16.61% | -12.34% | -10.74% | -163.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 370.38% | -16.61% | -12.34% | -10.74% | -163.27% |
| EBIT | 82.56% | -19.07% | -14.54% | -14.55% | -175.30% |
| EBITDA | 87.55% | -20.02% | -15.40% | -15.26% | -168.44% |
| EPS Basic | 317.68% | 6.31% | 9.34% | -2.85% | -161.77% |
| Normalized Basic EPS | 324.09% | -0.46% | -1.04% | -4.55% | -160.91% |
| EPS Diluted | 313.43% | 6.31% | 9.34% | -2.85% | -163.26% |
| Normalized Diluted EPS | 319.71% | -0.46% | -1.04% | -4.55% | -162.31% |
| Average Basic Shares Outstanding | 24.21% | 24.46% | 23.91% | 7.68% | 2.43% |
| Average Diluted Shares Outstanding | 26.69% | 24.46% | 23.91% | 7.68% | 0.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |